Novo Nordisk AS - Company Profile

Powered by

All the data and insights you need on Novo Nordisk AS in one report.

  • Save hours of research time and resources with
    our up-to-date Novo Nordisk AS Strategy Report

  • Understand Novo Nordisk AS position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Novo Nordisk AS (Novo Nordisk), a subsidiary of Novo Holdings AS, is a healthcare company with focus on discovering, developing, and manufacturing biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious and chronic conditions including haemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases and obesity. The company’s portfolio includes pre-filled delivery systems for insulin; glucagon hypokit; cartridge; needles; vials; insulin; estradiol for hormone replacement; recombinant drugs for haemophilia; glucagon; and oral antidiabetic agents. The company markets its products through subsidiaries in North America, Europe, Asia, Latin America, Africa, the Middle East and Australia. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Gain a 360-degree view of Novo Nordisk AS and make more informed decisions for your business Gain a 360-degree view of Novo Nordisk AS and make more informed decisions for your business Find out more
Headquarters Denmark

Address Novo Alle 1, Bagsvaerd, 2880


Telephone 45 44 448888

No of Employees 66,015

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange NOVO B (CPH)

Revenue (2022) $33.7B 31.3% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 50.7% (2022 vs 2021)

Market Cap* $480.4B

Net Profit Margin (2022) XYZ 14.8% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Novo Nordisk AS premium industry data and analytics

1,400+

Clinical Trials

Determine Novo Nordisk AS go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

690+

Catalyst Calendar

Proactively evaluate Novo Nordisk AS’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

680+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Novo Nordisk AS’s relevant decision makers and contact details.

210+

Pipeline Drugs

Identify which of Novo Nordisk AS’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

140+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Marketed Drugs

Understand Novo Nordisk AS’s commercialized product portfolio to stay one step ahead of the market.

40+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

40+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Novo Nordisk AS and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Investigators

Review investigator profiles and find information on trial contacts across Novo Nordisk AS, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

13+

IT Services Contracts

Improve competitive bidding with insights into all publicly disclosed IT services contracts for Novo Nordisk AS (including IT outsourcing, business process outsourcing, systems integration & consulting and more).

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Novo Nordisk AS’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Diabetes Delivery Systems: Rivfloza
Insulin Pens Tresiba
Injection Needles Ryzodeg
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Novo Nordisk AS portfolio and identify potential areas for collaboration Understand Novo Nordisk AS portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Plans/Strategy In June, the company announced its plans to invest US$4.1 billion to expand its manufacturing capacity in the US.
2024 Contracts/Agreements In May, the company partnered with Metaphore Biotechnologies to develop up to two next-generation therapeutics for obesity management.
2024 Plans/Strategy In March, the company announced its plans to acquire Cardior Pharmaceuticals, a biotech company.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Novo Nordisk AS Johnson & Johnson Merck & Co Inc Pfizer Inc Sanofi
Headquarters Denmark United States of America United States of America United States of America France
City Bagsvaerd New Brunswick Rahway New York Paris
State/Province - New Jersey New Jersey New York Ile-de-France
No. of Employees 66,015 131,900 72,000 88,000 87,994
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Helge Lund Chairman Executive Board 2018 62
Lars Fruergaard Jorgensen Chief Executive Officer; President Senior Management 2017 58
Karsten Munk Knudsen Chief Financial Officer; Executive Vice President Senior Management 2018 53
Marcus Schindler Executive Vice President - Research & Early Development; Chief Scientific Officer Senior Management 2021 58
Henrik Poulsen Vice Chairman Executive Board 2021 57
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Novo Nordisk AS key executives to enhance your sales strategy Gain insight into Novo Nordisk AS key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer